Hepatocyte growth factor (HGF) alleviates acute and chronic inflammation in experimental inflammatory bowel disease, glomerulonephritis, and airway inflammation. However, the anti-inflammatory effects of HGF on myocardial infarction are not defined. The current study assessed the anti-inflammatory effects of HGF in post-ischemic heart failure. The left anterior descending coronary artery was ligated in rats, and adenovirus containing human HGF (Ad-HGF) or control virus (Ad-GFP) was administered intramyocardially. The quantity of proinflammatory cytokines secreted by cardiomyocytes, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-1β, was evaluated. Cardiac function and LV remodeling were assessed using echocardiography and collagen deposition, respectively. Left ventricular fractional shortening (LVFS) and left ventricular ejection fraction (LVEF) four weeks after injection were significantly increased in Ad-HGF-treated animals compared to the Ad-GFP group. HGF gene therapy improved ventricular geometry with a significantly decreased left ventricular end-diastolic diameter (LVEDD) and markedly reduced myocardial collagen deposition. Treatment with Ad-HGF significantly decreased the mRNA levels of TNF-α, IL-6, and IL-1β in the non-infarcted region four weeks after injection. Changes of the TNF-α, IL-6, and IL-1β levels in the non-infarcted region positively correlated with the LVEDD 4 weeks after infarction. Treatment of acute myocardial infarction (AMI) with Ad-HGF in the early stage of MI reduced the pro-inflammatory cytokine levels and preserved cardiac function. These findings indicated that Ad-HGF gene therapy alleviated ventricular remodeling after infarction by reducing inflammation.
Cardiovascular–Kidney–Metabolic (CKM) syndrome, a concept recently introduced by the American Heart Association (AHA), emphasizes the intricate relationships among metabolic, renal, and cardiovascular diseases. The C-reactive protein–triglyceride–glucose index (CTI) has been proposed as an effective biomarker for insulin resistance (IR) and inflammation. Although there is substantial evidence demonstrating an association between the CTI and cardiovascular disease (CVD), its precise role in individuals with CKM syndrome stage 0–3 remains unclear. This prospective cohort study analysed data from China Health and Retirement Longitudinal Study (CHARLS), with a follow-up period of 10 years. The exposure variable was CTI at baseline, which was calculated as a combination of triglyceride (TG), fasting blood glucose (FBG), and C-reactive protein (CRP). The primary endpoint was the CVD. Cox proportional hazards regression and restricted cubic spline (RCS) analysis were conducted to examine the association between CTI and CVD risk. This study included 7,711 participants (52.38% female; mean age, 59.01 ± 9.37 years). An elevated CTI was significantly associated with a greater risk of developing CVD. Specifically, after fully adjusting for potential confounders, each one-unit increase in the CTI was associated with a 16% increase in CVD risk (hazard ratio [HR] = 1.16; 95% confidence interval [CI]: 1.06–1.27). Compared with participants in the lowest CTI group, those in the highest CTI group had a 42% greater CVD risk (HR = 1.42; 95% CI: 1.20–1.68). RCS analysis revealed a nonlinear association between CTI and the CVD risk among individuals with CKM syndrome stage 0–3 (overall P < 0.001; nonlinearity P = 0.01). This study revealed a positive association between CTI and CVD risk among individuals with CKM syndrome stages 0–3, suggesting that CTI may serve as a practical tool for CVD risk stratification in this population.
The clinical significance of stem cell therapy in the treatment of dilated cardiomyopathy remains unclear. This systemic appraisal and meta-analysis aimed to assess the efficacy and safety of stem cell therapy in patients with dilated cardiomyopathy. After searching the PubMed, Embase, and Cochrane library databases until November 2017, we conducted a meta-analysis to evaluate the efficacy and safety of stem cell therapy in patients with dilated cardiomyopathy. The weighted mean difference (WMD), standard mean difference (SMD), relative risk (RR), and 95% confidence interval (CI) were summarized in this meta-analysis. Both fixed effects and random effects models were used to combine the data. Sensitivity analyses were conducted to evaluate the impact of an individual dataset on the pooled results. A total of eight randomized controlled trials, which involved 531 participants, met the inclusion criteria in this systematic appraisal and meta-analysis. Our meta-analysis showed that stem cell therapy improves left ventricular ejection fraction (SMD = 1.09, 95% CI 0.29 to 1.90, I2 = 92%) and reduces left ventricular end-systolic volume (SMD = − 0.36, 95% CI − 0.61 to − 0.10, I2 = 20.5%) and left ventricular end-diastolic chamber size (SMD = − 0.48, 95% CI − 0.89 to − 0.07, I2 = 64.8%) in patients with dilated cardiomyopathy. However, stem cell therapy has no effect on mortality (RR = 0.72, 95% CI 0.50 to 1.02, I2 = 30.2%) and 6-min-walk test (WMD = 51.52, 95% CI − 24.52 to 127.55, I2 = 94.8%). This meta-analysis suggests that stem cell therapy improves left ventricular ejection fraction and reduces left ventricular end-systolic volume and left ventricular end-diastolic chamber size in patients with dilated cardiomyopathy. However, future well-designed large studies might be necessary to clarify the effect of stem cell therapy in patients with dilated cardiomyopathy.